MorphoSys (ETR:MOR) received a €116.00 ($134.88) price objective from equities researchers at Independent Research in a note issued to investors on Tuesday, Borsen Zeitung reports. The brokerage presently has a “neutral” rating on the stock. Independent Research’s price objective points to a potential upside of 6.03% from the stock’s previous close.
Several other analysts have also weighed in on MOR. Berenberg Bank set a €150.00 ($174.42) target price on MorphoSys and gave the company a “buy” rating in a report on Monday, August 5th. Goldman Sachs Group set a €114.00 ($132.56) target price on MorphoSys and gave the company a “neutral” rating in a report on Wednesday, August 7th. JPMorgan Chase & Co. set a €120.00 ($139.53) target price on MorphoSys and gave the company a “buy” rating in a report on Wednesday, August 7th. Royal Bank of Canada set a €130.00 ($151.16) target price on MorphoSys and gave the company a “buy” rating in a report on Friday. Finally, Deutsche Bank set a €133.00 ($154.65) target price on MorphoSys and gave the company a “buy” rating in a report on Thursday, August 8th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and five have assigned a buy rating to the company. MorphoSys has a consensus rating of “Hold” and an average price target of €115.78 ($134.63).
MorphoSys stock traded up €0.60 ($0.70) during trading hours on Tuesday, hitting €109.40 ($127.21). The stock had a trading volume of 104,236 shares, compared to its average volume of 153,687. The company has a quick ratio of 7.40, a current ratio of 7.62 and a debt-to-equity ratio of 8.61. The company has a market cap of $3.45 billion and a PE ratio of -82.82. MorphoSys has a 1-year low of €76.45 ($88.90) and a 1-year high of €114.60 ($133.26). The firm has a fifty day simple moving average of €98.03.
MorphoSys AG, together with its subsidiaries, develops and commercializes antibodies and peptides for therapeutic applications in the United States. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 115 drugs for various diseases, such as psoriasis, Alzheimer's diseases, haematological malignancies, solid tumors, hemophilia, multiple myeloma, metabolic diseases, inflamation, thrombosis, brittle bone syndrome, eye diseases, cancers, diabetic eye diseases, blood disorders, and asthma.
Featured Article: What are Bollinger Bands?
Receive News & Ratings for MorphoSys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MorphoSys and related companies with MarketBeat.com's FREE daily email newsletter.